Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

Introduction Vaccines are biological preparations that stimulate the immune system to develop protection against specific infectious diseases.

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

CFO Octavio Espinoza sold 5,000 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia.

Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine, a ...

In addition to increasing vaccine coverage in older adults, they need to monitor the changing epidemiology of pneumococcal serotypes causing invasive disease. [134] In the face of these changes ...

Reading a pamphlet in the doctor's office about which vaccines to get may help nudge older adults to get vaccinated.

Pneumococcal conjugate vaccines (PCVs) are known to provide protection against vaccine serotype pneumococcal pneumonia; uncertainty exists regarding the optimum PCV dosing schedule. Methods ...